tatCN19o
Multiple CNS disorders (Global cerebral ischemia, Spinal cord ischemia, Stroke, Alzheimer's disease)
Pre-clinicalActive
Key Facts
Indication
Multiple CNS disorders (Global cerebral ischemia, Spinal cord ischemia, Stroke, Alzheimer's disease)
Phase
Pre-clinical
Status
Active
Company
About Neurexis Therapeutics
Neurexis Therapeutics is a private, preclinical-stage biotech founded in 2018 and based in San Diego, operating in the RNA & Gene Therapy sector. The company is advancing tatCN19o, an optimized peptide therapeutic designed to directly prevent neurodegeneration and restore function by targeting a critical node in the glutamate excitotoxicity pathway. Its strategy targets multiple high-value CNS indications with no approved neuroprotective therapies, representing large, untreated markets. The company appears to be in an early development stage, likely supported by venture or incubator funding.
View full company profile